Healthcare · Pharmaceuticals & Biotechnology
QVM read Quality business Quality Strong, Valuation Expensive, Momentum Neutral
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company based in Mumbai. Founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer, it is listed on the Bombay Stock Exchange and the National Stock Exchange of India. The company produces and distributes medicines in more than 80 countries, with operations concentrated in India, North America, Europe, and emerging markets. As of March 2026, it employed approximately 17,000 people. Its name derives from Saldanha's sons, Glenn and Mark.
Source: Wikipedia
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Ranks #11 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Filed | Person | Category | Type | Quantity | Value |
|---|---|---|---|---|---|
| 25 Sep 2023 | Mr. Praveen D Kurkal | Employee / designated person | Sell | 0 | ₹0 |
| 25 Sep 2023 | Mr. Praveen D Kurkal | Employee / designated person | Sell | 0 | ₹0 |
| 25 Sep 2023 | Mr. Praveen D Kurkal | Employee / designated person | Sell | 0 | ₹0 |
| 24 Nov 2021 | Robin Pinto | Promoter group | Buy | 0 | ₹0 |
| 17 Nov 2021 | SRIDHAR GORTHI | Director | Sell | 0 | ₹0 |
| 29 Sep 2021 | NEHA SALDANHA | Promoter group | Buy | 0 | ₹0 |
| 29 Sep 2021 | RAYNA MARIE SALDANHA | Immediate relative | Sell | 0 | ₹0 |
| 29 Sep 2021 | AISHA LOUISE SALDANHA | Immediate relative | Sell | 0 | ₹0 |
| 27 Sep 2021 | Glenn Mario Saldanha | Promoter | Buy | 0 | ₹0 |
| 23 Sep 2021 | Cherylann Maria Pinto | Promoter | Buy | 0 | ₹0 |
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 11 Jul 2025 | GRAVITON RESEARCH CAPITAL LLP | Bulk | Sell | 1,510,591 | 2173.3100 | NSE |
| 11 Jul 2025 | GRAVITON RESEARCH CAPITAL LLP | Bulk | Buy | 1,510,591 | 2171.6700 | NSE |
| 25 Mar 2025 | UBS AG | Block | Sell | 264,465 | 1492.6500 | NSE |
| 25 Mar 2025 | INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD. | Block | Buy | 264,465 | 1492.6500 | NSE |
| 25 Mar 2025 | UBS AG | Block | Sell | 264,465 | 1492.6500 | NSE |
| 25 Mar 2025 | INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD. | Block | Buy | 264,465 | 1492.6500 | NSE |
| 23 Jan 2025 | UBS PRINCIPAL CAPITAL ASIA LIMITED | Block | Sell | 671,394 | 1510.0000 | NSE |
| 23 Jan 2025 | UBS AG | Block | Buy | 671,394 | 1510.0000 | NSE |
| 25 Oct 2022 | ISHARES MSCI INDIA SMALL-CAP ETF | Block | Buy | 39,265 | 397.9000 | BSE |
| 25 Oct 2022 | ISHARES INDIA SC MAURITIUS COMPANY | Block | Sell | 39,265 | 397.9000 | BSE |
| Ex-date | Subject | Per share (₹) | Record date |
|---|---|---|---|
| — | Final Dividend - Rs. - 2.5000 | — | — |
| 31 Aug 2026 | Dividend - Rs 2.50 Per Share | 2.5000 | 31 Aug 2026 |
| 3 Oct 2025 | Interim Dividend - Rs 2.50 Per Share | 2.5000 | 3 Oct 2025 |
| 15 Sep 2025 | Dividend - Rs 2.50 Per Share | 2.5000 | 15 Sep 2025 |
| 13 Sep 2024 | Dividend - Rs 2.50 Per Share | 2.5000 | — |
| 18 Sep 2023 | Dividend - Rs 2.50 Per Share | 2.5000 | — |
| 12 Sep 2022 | Annual General Meeting/Dividend - Rs 2.50 Per Share | 2.5000 | — |
| 8 Sep 2021 | Annual General Meeting/Dividend - Rs 2.50 Per Share | 2.5000 | — |
| 17 Sep 2020 | Annual General Meeting/Dividend - Rs 2.50 Per Share | 2.5000 | — |
| 19 Sep 2019 | Annual General Meeting/Dividend - Rs 2 Per Share | 2.0000 | — |
Bonuses, splits, buybacks and other events. Dividends are listed separately above.
| Ex-date | Type | Subject |
|---|---|---|
| 10 Sep 2007 | SPLIT | Agm/Fv Split Rs.2 To Re.1 |
| 10 Sep 2009 | AGM | Agm/Div-Re.0.40 Per Share |
| 18 Sep 2008 | OTHER | Annual General Meeting |
| 25 Sep 2006 | AGM | Agm |
| 22 Sep 2005 | AGM | Agm |
Quarterly results, AGMs, buybacks and other board-approved business.
| Date | Purpose | Results |
|---|---|---|
| 31 Jul 2026 | Financial Results | Yes |
| 29 May 2026 | Financial Results/Dividend | Yes |
| 30 Jan 2026 | Financial Results | Yes |
| 14 Nov 2025 | Financial Results | Yes |
| 26 Sep 2025 | Dividend | — |
Exchange disclosures (NSE and BSE), most recent first.
| Date | Category | Announcement |
|---|---|---|
| 28 Sep 2026 | Insider Trading / SAST | Glenmark Pharmaceuticals Ltd - 532296 - Closure of Trading Window |
| 28 Sep 2026 | Trading Window | Glenmark Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
| 23 Sep 2026 | Press Release | Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 23, 2026, titled "Glenmark Pharmaceuticals receives Establishment Inspection Report (EIR) from U.S. FDA for its Goa facility with VAI classification". |
| 21 Sep 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Glenmark Pharmaceuticals Limited has informed the Exchange about Schedule of meet |
| 21 Sep 2026 | Company Update | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation |
| 11 Sep 2026 | AGM/EGM | Glenmark Pharmaceuticals Ltd - 532296 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report |
| 11 Sep 2026 | AGM/EGM | Glenmark Pharmaceuticals Ltd - 532296 - Shareholder Meeting / Postal Ballot-Outcome of AGM |
| 11 Sep 2026 | Company Update | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release |
| 11 Sep 2026 | Company Update | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Credit Rating |
| 11 Sep 2026 | Shareholders meeting | Glenmark Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 11, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results. |
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Data unavailable.
Board of directors and corporate information →
Single-stock futures and a real listed options chain available for this stock -- OI buildup, PCR, Max Pain and Greeks are all on the full F&O page.
Part of: NIFTY 200, NIFTY 200, NIFTY 500, NIFTY 500, NIFTY MIDCAP 100, NIFTY MIDCAP 100, NIFTY MIDCAP 150, NIFTY MIDCAP 150, NIFTY MIDCAP 50, NIFTY PHARMA, NIFTY PHARMA
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
